Fibroblasts derived from the involved skin of scleroderma patients frequently display a phenotype of supernormal collagen expression when cultured. Fibroblasts displaying this phenotype derived from seven patients were treated with r~laxin (1-100 ngjml) and interferon-y (1-100 U jml), individually and in combination, to assess the relative abilities of these cytokines to down-modulate collagen synthesis and S~cretion. Scleroderma fibroblasts displayed varying sensitivities to both relaxin and interferon-yo Relaxin (100 ng/ml) decreased expression of collagen by six of seven lines tested from 8 to 59% compared to untreated cultures. Interferon-y (100 U jml) depressed collagen secretion by all seven lines in C onnective tissue turnover is normally an orderly process in which the breakdown of extracellular matrix molecules is offset by the synthesis of new elements. This balance, which is critical to normal growth and development, is temporarily altered in response to traumatic or pathologic tissue injury to effect tissue repair. However, in certain pathologies, such as scleroderma (progressive systemic sclerosis) , this balance is chronically skewed in the direction of matrix over-production, resulting in excessive fibrosis of the skin, gastrointestinal tract, and other organ systems [1] . Fibroblasts cultured from scleroderma lesions synthesize increased amounts of collagen [2, 3] ' glycosaminoglycans [4] , and fibronectin [4, 5] . This unregulated expression of extracellular matrix molecules is thought to be. responsible for much of the tissue and organ damage manifest in thiS disease.
We have previously shown that synthetic human relaxin can doWn-regulate the collagen secretory phenotype of normal human
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Manuscript received January 22, 1992 ; accepted for publication March 25, 1992. This work was supported in part by NIH grant R37 AR19537. Portions of this work were presented at the annual meeting of the American College of Rheumatology inJune, 1989, and have been published as an abstract (Arthritis Rheum 32: S33, 1989 dermal fibroblasts, especially when the cells are stimulated to overproduce collagen, such as by treatment with the cytokines transforming growth factor-p (TGF-P) or interleukin-1p (IL-IP) [6] . This occurs in conjunction with a dose-dependent increase in the secretion of the metalloproteinase procollagenase and a small decrease in tissue inhibitor of metalloproteinases, suggesting that relaxin may be able to modulate connective tissue turnover in favor of net collagen breakdown in situations of collagen overexpression.
Previously published work has shown that interferon-y (IFN-y) is a potent down-regulator of collagen expression in scleroderma [7] , normal [8] [9] [10] ' and rheumatoid synovial [10] fibroblasts. These findings were the bases of the current work, in which scleroderma fibroblasts were treated with relaxin alone and in conjunction with IFN-y to see i) whether relaxin could down-regulate collagen secretion in these fibroblasts and ii) whether the combination of relaxin and IFN-y could be as or more effective than either agent individually in effecting a significant decrease in collagen secretion.
METHODS
Cell Culture Scleroderma fibroblast cell lines were derived from full-thickness skin biopsy specimens from patients who fulfilled the American Rheumatism Association criteria for the diagnosis of scleroderma [11] . Paired skin biopsies from the uninvolved skin of patients were also available in some cases. Explant cultures were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 2 mM L-glutamine until a confluent monolayer of fibroblasts had been established. Cultures were then expanded using a 1: 3 split in DMEM-FBS until an adequate number of cells was obtained for experiments. Normal dermal fibroblasts obtained from explant culture of normal human skin obtained from rhytidectomy or from the American Type Culture Collection (ATCC CRL1471) were used between passages 1 and 7. Cells were counted at each passage using a hemocytometer to assess saturation densitites of the different lines. cultures were subjected to digestion with purified bacterial collagenase at 37 0 C for 6 h. precipitated. and electrophoresed on a 7% polyacrylamide gel. Procollagens. which migrate as several partially processed bands in the absence of bacterial collagenase (bact eL) digestion (-) . are degraded in the presence of collagenase (+). (B) Autoradiograms. which included procollagen precipitated from both normal and scleroderma cultures. were scanned desnitometrically. Densities were plotted such that the average amount of procollagen expressed by normal cultures of dermal fibroblasts was equivalent to 1.0. Densitometric values were normalized for differences in saturation density of the cultures. Seven lines secreted 1.5 -4.3 times more procollagen than normal cells on a per cell basis. Labeled proteins resolved by electrophoresis were analyzed densitometncally on autoradiograms. Lines were found to respond consistently to treatments among experiments. Bar. average of two replicate cultures within one experiment. Standard error was less than 10% in each case.
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For experiments. all cells were seeded at 6.25 X 10 4 cells/cm 10 DMEM + FBS in 24-or 48-well plates. At 72 h. the cells were washed and the medium replaced with DMEM supplemented with 0.2% lactalbumin hydrolysate and 2 roM L-giutamine. Cells were treated with cytokines in this serum-free medium for 48 h.
Reagents Bioactive human relaxin was either chemically synthesized as predicted from the sequence of the human relaxin gene I-I2 [12] or expressed as a recombinant protein in a mammalian expression system [13] . No differences in bioactivity have been noted 10 the relaxin from the two sources. IFN-y was recombinant. human (Genentech. specific activity 2.65 X 10 7 U/mg) [14] . Asco~bate and /l-aminopropionitrile (BAPN) were purchased from Sigma and prepared as 50 and 80 mg/ml stocks. respectively. in DME~ 
Biosynthetic Labeling and SDS-PAGE For analysis of colla-
gen synthesis and secretion. cells were labeled with 3H-proline (2~ ,uCi/ml) in DMEM in the presence of 50 ,ug/ml ascorbate and 8 ,ug/ml BAPN for 18 h at 37°C. In experiments where cultures were treated with IFN-y and relaxin. cytokines were present during the labeling period. Biosynthetically labeled secreted proteins were precipitated from the conditioned media using 0.02 M quinine sulfat d and 0.2% SDS [15] . resuspended in Laemmli sample buffer [1 . 6] . an I electrophoresed on 7% polyacrylamide gels using a 3% stacking gi. under reducing conditions according to the method of Laemrn I [16] . In some experiments. radiolabeled proteins were tested for sensitivity to bacterial collagenase (100 units/ml) (Advance BiOfa ctures) for 6 h at 37°C to identify collagenous proteins [15] . collagens were also characterized according to migration on a 5% polya c d rylamide gel following limited pepsin digestion [17] and delayed reduction [18] . Gels were enhanced (New England Nuclear). dne .
and exposed to X-Omat film (Kodak) at -80°C. Collagen bands 0;.
the radiograms were scanned densitometrically on a Microtek 0 S 300GS .image scanner and the areas under the entire bands 1I1 tegrated using the National Institutes of Health Image 1.23 h program on a MacIntosh II computer (Apple Computers) . I To assess the relative effects of relaxin and IFN-y on the to.t~ amount of protein secreted. cultures were also labeled for 18 ~ WI~ 1 [35S]-methionine (25 ) .lCi/ml) in methionine-free DMEM 111 t/ presence of cytokines. Protein was precipitated from the cond 1_ tioned media with quinine-sulfate-sodium dodecyl sulfate. as e scribed above. and aliquots counted in a scintillation counter. • Collagen bands on auto radiograms were scanned densitometrically to quantitate effects of relaxin and IFN-y on collagen protein expression by seven scleroderma (SD) hnes . All lines were su bjected to nine treatment regimens in duplicate in at least two eXperi ments. Decreases in collagen expression induced by treatments were consistent among experiments for each line. %t. was obtained by calculating the average change in Collagen expression by cultures treated in duplicate with that of the untreated control culture in one representative experiment. Standard error was less than 10% in each case.
b Relaxin effect was assessed at 100 ng/m!.
' IFN_y effect was observed at 100 U/m!.
RESULTS
All scleroderma lines included in this study demonstrated enhanced collagen expression when compared to normal dermal fibrob lasts or fibroblasts from the uninvolved skin of the same patient, when available, as ascertained by densitometric analysis of labeled collage n bands on autoradiograms, as described below. Normal and scleroderma fibroblasts were labeled in DMEM in the absence of serum for 18 h with 3H-proline in the presence of ascorbate, a co-factor required for collagen synthesis, and BAPN, an agent that inhibits c.ollagen cross-linking, as described in the Materia ls and Methods section. Biosynthetically labeled secreted proteins from normal and s~l eroderma cultures were precipitated from equal volume~ of conditioned media and electrophoresed on 7% polyacrylamide gels. Procollagen was identified as the two most prominent proline-incorporating bands on the radiogram by sensitivity to digestion by purified bacterial collagenase (Fig 1A) . To provide a normal reference for relative quantity of collagen synthesized by scleroderma RELAXIN AND INTERFERON-y DECREASE COLLAGEN 339 fibroblast cultures, procollagen precipitated from a normal fibroblast culture was electrophoresed alongside those from scleroderma cultures. Procollagen bands were scanned densitometrically, as described in the Materials and Methods section; these areas were plotted as relative numbers such that the amount of collagen secreted by a normal dermal fibroblast culture was equal to 1.0. Differences in the saturation densities of the cell lines at confluence were noted (data not shown); therefore, values for relative amount of collagensynthesized were normalized for cell number per culture dish. Scleroderma lines were compared with normal cultures over two-four experiments and lines whose comparative collagen expression values were higher than normal by at least 50% were selected for this study. Seven scleroderma lines secreted 1.5 -4.3 times more collagen than normal fibroblasts (Fig IB) and were analyzed for responsiveness to cytokine treatment.
To assess the sensitivity of cultures of scleroderma cultures to relaxin, cells were cultured as described above and treated 72 h later in duplicate wells with relaxin (1,10, and 100 ng/ml) for 48 h . At the end of this period, cells were labeled with 3H-proline in the presence of cytokines, ascorbate, and BAPN for 18 h . All seven lines were tested in two separate experiments and response patterns were consistent between experiments for each line. Three lines, SDll , SD 16, and SD 17, were sensitive to relaxin treatment and manifested dose-dependent decreases in collagen expressiolJ., with maximum decreases of 29%, 59%, and 76%, respectively, at a relaxin dose of 100 ng/ml (Fig 2) . Three other scleroderma lines demonstrated smaller decreases in collagen expression ranging from 8% to 14% in response to relaxin (100 ng/ml) ( Table I) . One line, SD18, showed no consistent response to relaxin. Total secreted protein, as assessed by [35S)methionine incorporation into quinine sulfate-SDS -precipitable material, increased 25% over control levels with the maximum dose of relaxin.
The seven scleroderma lines were tested individually for IFN-y sensitivity (100 U /ml) and responded with decreases in collagen synthesis and secretion from ranging from 7 to 89% (Table I) . These results are consistent with previously published reports on the effects ofIFN-y on collagen expression by scleroderma fibroblasts [9) .
The ability of relaxin and IFN-y to alter patterns of collagen expression when used in combination was then tested on the scleroderma fibroblasts. Scleroderma cultures were treated with relaxin 1), and a t(III) chains are equally decreased from untreated levels (-) following treatment (+) with relaxin (100 ng/ml) and FN_y (100 V/ ml).
(1,10, and 100 ng/ml) in combination with IFN-y (1,10, and 100 U /ml) such that all three relaxin doses were tested in conjunction with all three doses of IFN-y, resulting in nine combination treatment groups. Four of seven lines tested demonstrated a cooperative effect of using both cytokines together in depressing collagen expression. Scleroderma line, SD5, which demonstrated responses of moderate magnitude to relaxin and IFN-y individually (Table I) , showed striking decreases in secreted collagen in the presence of both cytokines (Fig 3A,B , Table II) . A suboptimal dose ofIFN-y (10 U /ml) in conjunction with low concentrations of relaxin (1 and 10 ng/ml) effected decreases of 58% and 62% in collagen expression, depressions not approached when maximum doses of either relaxin (100 ng/ml) or IFN-y (100 U/ml) were used individually. The augmenting effect of relaxin on collagen 'depression occurred in a dose-dependent manner. Limited pepsin digestion and delayed reduction analysis of the collagen chains demonstrated roughly equivalent decreases in expression of the a l (I), ail), and a l (III) chains by treatment with the combination of cytokines (Fig 3C) . The coordinate decreases in expression of all three chains that comprise types I and III procollagens were similar to changes induced by IFN -Y alone [10] . In the cases ofSDll and SD18, the addition of relaxin in conjunction with suboptimal concentrations ofIFN-y resulted in decreases in collagen secretion equivalent to that seen following treatment with a tenfold higher dose of IFN-y (Fig 4) . Treatment of SDll fibroblasts with relaxin (100 ng/ml) or IFN-y (10 U /ml) individually caused a 29% or 41 % decrease in collagen expression, respectively (Fig 4A) . The addition of the two agents together resulted in a 53% decrease, equivalent to that seen when IFN-y was used at a tenfold higher concentration, 100 U/ml (Table II) . SD18 showed no consistent. response to treatment with relaxin alone but when relaxin was used in combination with IFN-y, decreases in collagen expression exceeded that seen by using IFN-y alone (Fig 4B) . Another scleroderma line, SD14, which was relatively resistant to relaxin and IFN-y when the cytokines were tested individually, demonstrated an additive response when they were used in combination. Whereas IFN-y and relaxin individually effected 7% and 8% depressions in collagen expression, respectively, their combination resulted in a 17% decrease in collagen secreted (Table II) . No additive or synergistic effects of the two cytokines were observed following treatment of scleroderma lines SD 10, 16, or 17. None of the combination treatments caused a change in total secreted protein (data not shown).
DISCUSSION
The coordinated assembly and disassembly of collagen and other matrix elements allows for tissue growth and repair and provides developmental and differentiation cues that are critical to proper form and function of multicellular animals. When this precise regulation of connective tissue turnover is disrupted, severe problems in form and function do occur. Fibroblasts derived from the sclerotic skin of scleroderma patients can demonstrate markedly elevated levels of collagen synthesis and secretion as compared to normal dermal fibroblasts [2, 3] . The overproduction of collagen and other extracellular matrix constituents [4, 5] are thought to cause the progressive fibrosis that leads to tissue damage in this disease. Previously reported work has shown that IFN-y can be effective in decreasing collagen synthesis in scleroderma fibroblasts [7] . These and subsequent studies that have shown that IFN-y can decrease collagen accumulation in vivo [19 -21] were the bases for the initiation of limited clinical trials to test the efficacy of IFN-y in the treatment of scleroderma and ke10ids [22] [23] [24] . The hormone relaxin has been shown to be effective in decreasing collagen expression in normal dermal fibroblasts in vitro, particularly when significant collagen overexpression is induced by the cytokines TGF-fi or IL-lfi [6] . Recently, we have also shown that relaxin is capable of inhibiting fibrosis in two animal models [25] . In the present study, we have extended these findings by demonstrating that relaxin can down-regulate collagen expression in scleroderma fibroblasts and Treatment ofSpl fibroblasts with relaxin alone had no effect but the addition of rel ax1l1 / t1 lFN-y (1 V/ml) resulted in a decrease greater than that seen with 10 U md IFN-y. Bar, average of two replicate wells within one experiment. Standar error was less than 10% in each case.
have also shown that the two collagen inhibitory cytokines, rela~in
and IFN-y, have greater potential utility when used in combinatiOn than when used individually. Consistent with our previous findings that relaxin is a potent collagen down-regulatory cytokine under conditions when c~lls a~e overproducing collagen, relaxin can depress collagen express lOll 11
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scleroderma fibroblasts that are stimulated to produce excess co gen. The basis for the differences in sensitivity of the sclerod errn 
• Decreases in collagen expression were calculated as described in Table I . b Relaxin effect obtained at a dose of 100 ng/ml in all cases. , IFN-yeffect observed at 10 Vlml for 5011,1 Vim I forSOl8, and at 100 Vlml for SDS and S014.
'Effect of combining relaxin and IFN-y at doses used in individual treatments, descnbed in footnotes band c.
roderma" may actually represent a cluster of diseases manifesting a similar collagen-overexpressing phenotype is a further complicatIng factor. However, the question of differences in relaxin binding to scleroderma lines displaying high and low sensitivity to relaxin is now being addressed by doing binding studies using radiolabeled relaxin.
The mechanism by which relaxin depresses collagen expression is undetermined but its abi lity to do so under a variety of conditions Suggests an important target. For example, r~laxin can inhib~t collagen synthesis by normal dermal fibroblasts m culture, parucularly when stimulated by TGF-p or IL-1P in the presence of mdomethaCin [6] . It is also a potent collagen inhibitory agent in vivo, as demonstrated when tested in two rodent models of fibrosIs [25] m which a number of cytokines are likely to be participating in stimulating coliagen synthesis. Therefore, the fact that it can also decrease collaen secretion by scleroderma fibroblasts suggests that it is impi~g Ing at a common point in the collagen stimulatory pathways tnggered by a number of agonists. IFN-y has been reported to decrease Collagen expression primarily by causing mRNA instability [28] . Its additive or synergistic cooperativity with IFN-y in decreasmg collagen expression suggests complex interactions between the two cytokines; interactions at the intracellular signaling pathway level or at the level of receptor number or affinity cannot be excluded.
The systemic administration of IFN-y to humans at pharmacologic doses is accompanied by some adverse reactions, predominantly flu-like symptoms [23, 24, 27] . Consequently, it is desirable to. keep the administered dose as low as possible while still maintaining the desired effect. In the [resent study, we evaluated the effectiveness of the combination 0 IFN-y and relaxin in decreasing coliagen expression by scleroderma fibroblasts in vitro. We have found that in four of seven scleroderma lines, relaxin was able to augment the collagen-depressing effect of INF-y. In three of the b nes , the addition of relaxin to cultures in combination with suboptimal concentrations of IFN -y resulted in decreases in collagen expression equivalent to or better than that obtained by IFN-y alone at i t<:nf?ld higher concentration. This demonstrates that usi~g reaXIn In conjunction with IFN-y may allow for a reduction m t~e concentration ofIFN-y necessary to achieve a significant decrease m COliagen expression. In another of the lines, which was relatively Insensitive to either relaxin or IFN-y when used individually, the Combination of cytokines at the maximum in vitro doses'effected an additive decrease in collagen secretion.
Because relaxin is a naturally occurring hormone of pregnancy [12] , it is likely to be well-tolerated if given exogenously. In addition, studies published in the late 1950s and early 1960s reported sOme efficacy of partially purified procine relaxin in the treatment of scleroderma patients [28, 29] ' particularly with regard to increasIng skin elasticity and healing of skin ulcers. However, the ability of relaxin to be evaluated further was limited by uncertainties concerning the source and purity of relaxin preparations [29] . The availability of highly purified, human recombinant relaxin will now RELAXIN AND INTERFERON-y DECREASE COLLAGEN 341 allow a full evaluation of its potential role, alone and in combination with IFN-y, as a modulator of excessive collagen synthesis in vitro and in vivo.
